SMT bio Co., Ltd.
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer (NCT05429697) | SMT bio Co., Ltd. | 2022-06-09 |
| Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer (NCT03937895) | SMT bio Co., Ltd. | 2019-12-03 |
Track SMT bio Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.